Background: Urinary tract infections (UTIs) are commonly reported by people with multiple sclerosis (PwMS) and significantly impact quality of life. Objective: To provide an overview of the problem of UTIs in PwMS and offer a practical approach for the diagnosis and management. Methods: A review of the literature through a Pubmed search up to October 2015 was performed using the following keywords: multiple sclerosis, neurogenic bladder, urinary tract infections, relapse, dipsticks, culture, recurrent and prevention. Results: Noteworthy topics include the definition of a confirmed symptomatic UTI as a positive urine culture defined by >10 5 colony-forming units (CFU)/mL or >10 4 CFU/mL if a urethral catheter urine sample is taken, or any count of bacteria in a suprapubic bladder puncture specimen, both in addition to symptoms including fever, pain, changes in lower urinary tract symptoms or neurological status. Urinalysis is useful to exclude a UTI; however, on its own is insufficient to confirm a UTI, for which urine culture is required. Experts advise asymptomatic UTIs should not be treated except in the context of an acute relapse. From international guidelines, there is no validated strategy to prevent recurrent UTIs in PwMS. Conclusion: This review provides an overview of the diagnosis, treatment and prevention of UTIs in the setting of multiple sclerosis (MS).
Introduction
Urinary tract infections (UTIs) commonly occur in multiple sclerosis (MS). Although a figure of 30% is often cited, estimates vary between 13% and 80% per patient life and this may be put down to the different patient cohorts studied. 1 However, this is also likely to reflect the lack of a consensus definition or diagnostic criteria for a UTI in patients with neurological disorders such as MS. 1 In general, the likelihood of infection is greater with longer disease duration and higher Expanded Disability Status Scale (EDSS) score, 2, 3 although UTIs may occur at any time point during the course of the disease. 1 UTIs are ranked among the top three reasons for hospitalization, being responsible for 30%-50% of all in-patient admissions of people with multiple sclerosis (PwMS). 4, 5 A prospective study of 73 patients with relapsingremitting MS demonstrated an increased risk of exacerbation around the time of infections, particularly UTI 6 and that infection-related relapses were associated with more sustained neurological deficits and worse quality of life compared to exacerbations not associated with infections, due to the burden of frequent hospitalizations and worsened lower urinary tract (LUT) symptoms. 6, 7 There is also evidence to suggest that UTIs were a significant predictive factor for death in MS, 3 and a retrospective analysis of a large validated UK primary care database 3 found that survival in MS was influenced not only by the underlying disease but also by other comorbidities such as UTIs, as well as other infections, heart disease and cancer, and lifestyle factors such as smoking and alcohol abuse.
Despite the burden of this problem, there is relatively little guidance around the evaluation and management of UTIs in PwMS. 1, 7, 8 We provide here an overview of the problem of UTI in MS by reviewing the existing evidence on the subject. Based on this review of the literature and on our practice in a centre of excellence, we offered a practical approach for the diagnosis, treatment and prevention of UTIs in PwMS.
Diagnosis of UTI

Symptoms of UTI
Recognizing UTI in PwMS can be difficult since PwMS suffering from UTI may not report the symptoms typically associated such as fever, rigour, suprapubic or flank pain, urinary urgency, frequency or worsening urinary incontinence and haematuria. Conversely, symptoms that may trigger suspicion of UTI in the general population, such as urinary urgency, frequency and incontinence, may reflect chronic LUT dysfunction in PwMS and not signify infection. 9 A UTI may need to be suspected in the presence of vague non-specific symptoms such as back or abdominal discomfort, reduced appetite or lethargy, deterioration of neurological status, leakage between intermittent self-catheterization (ISC), catheter blockage or the report of a cloudy urine with increased odour. 10 These symptoms are highly sensitive (77%-95%) for a UTI; however, they have low specificity (<50%). 11 
Urinalysis
Urinalysis (urine dipstick test) provides a rapid method of screening for UTIs. The test for leukocyte esterase detects the presence of azurophilic granules of monocytes and granulocytes (neutrophilic, eosinophilic and basophilic) whereas the test for nitrites is a rapid screening method for possible infections caused by nitrate-reducing bacteria such as Escherichia coli, Enterobacter, Klebsiella, Citrobacter and Proteus.
The presence of nitrites in the urine has a sensitivity of 45%-60% and specificity of 85%-98% for a UTI, leukocyte esterase test positivity a sensitivity of 48%-86% and specificity of 17%-93% and combined nitrites and leukocyte esterase test positivity (with one or both showing a positive result) a sensitivity of 75%-92% and specificity of 65%-87% depending on the study population and independently of the method of urine collection, as reported by a meta-analysis which included general population, children, pregnant women, elderly patients, urological patients, surgical patients and patients with spinal diseases. 12 However, specific data regarding MS population are lacking.
There are limitations to the use of urine dipsticks. Leukocyte esterase activity is not specific for a UTI and may be positive (and nitrites negative) in patients using a urinary catheter in the absence of UTI or in patients already using antibiotics. On the other hand, not all bacteria reduce nitrates in the urine to nitrites, and relying on urinalysis alone may miss infections due to Enterococcus.
In a meta-analysis of 70 studies evaluating the diagnostic accuracy of urinalysis, Devillé et al. 12 concluded that testing with urinalysis was useful to exclude UTI in all groups including neurological patients, if the results for nitrites or leukocyte esterase testing were negative. Indeed, a negative predictive value of 95% was reported when the combined nitrite and leukocyte esterase test was measured against culture. 13 Therefore, urinalysis for the presence of nitrites and leukocyte esterase is useful to rule out an infection (negative predictive value 95%). However, since the negative predictive value is not as 100%, it is advisable to send a urine culture if there is a high clinical suspicion for a UTI such as malodourous or turbid urine, despite a negative dipstick.
Urinalysis has a relatively low ability to diagnose an infection (positive predictive value <76%), thus, if urinalysis is positive, this should be followed up with urine culture to confirm whether indeed an infection is present. Figure 1 gives a suggested algorithm.
Urine culture
The gold standard for UTI diagnosis is urine culture as recommended by international guidelines. 8, 14 Urine specimens may be collected either as a clean-catch midstream sample, from an indwelling urethral catheter or a suprapubic aspiration from a suprapubic catheter. 14 Urine microscopy provides information about the cell types in the urine, and the term leukocyturia is used when there are more than 10 white blood cells per high-power field (400×) in the re-suspended sediment of a centrifuged aliquot of urine or per mm 3 in unspun urine. 14 Urine is routinely cultured on nutrient-dense medium and incubated over 2 days before it is said to be negative.
The definition for significant bacteriuria depends upon how the urine sample is collected. For a routine clean-catch midstream sample, a significant growth of bacteria is defined by counts of >10 5 colony-forming units (CFU)/mL. 14 For a urethral catheter urine sample, >10 4 CFU/mL may be considered relevant whereas for a suprapubic bladder puncture specimen, any count of bacteria is relevant. 14 In patients with a neurogenic bladder, Escherichia coli is the most common isolated pathogen (50%), followed by Pseudomonas aeruginosa (15%), Acinetobacter (15%), Enterococcus faecalis (6%) and multiorganismic infections. 15, 16 This is in contrast to the pathogens cultured in UTIs in the general population which are Escherichia coli (90%), Proteus (5%) and Klebsiella (4%). 14 Organisms such as Chlamydia and Ureaplasma urealyticum should be considered in patients with leukocyturia and negative routine cultures.
Patients using catheters may often consistently have uropathogens cultured form their urine (known as asymptomatic bacteriuria) 14 and therefore periodically sending urine samples for culture should be discouraged in the absence of fresh neurological or urological symptoms. Positive urine culture should be followed by identification of sensitivities to antibiotics in order to decide treatment.
Recurrent UTIs
Some PwMS experience recurrent UTIs and though a standard definition is lacking, according to the 2015 guidelines of the European Association of Urology, a patient reporting at least three episodes of UTIs documented by culture in the past 12 months or two UTI episodes in the preceding 6 months is said to have recurrent UTIs. 14 Risk factors for recurrent UTIs in MS have been poorly studied; however, it is thought that the presence of LUT dysfunction such as detrusor overactivity, detrusor sphincter dyssynergia or incomplete bladder emptying with large post-void residual volumes, the use of urinary catheters, the presence of vesicoureteric reflux, female gender and the use of immunosuppressive treatment increases the likelihood of UTIs in MS. 2, 17, 18 Increasing functional dependence is associated with greater difficulties in toileting and personal hygiene and may increase the risk of UTIs. Urinary retention increases the risk of UTIs 2,8 because of the multiplication of bacteria due to stagnation of urine in the bladder. It is therefore recommended by a UK consensus on the management of the bladder in MS and the French speaking group of neuro-urology (GENULF) that patients with high post-void residuals >100 mL measured either by ultrasound or single in-out catheterization should be considered for regular ISC to reduce the risks of UTI. 1, 8, 17 However, the use of either indwelling or intermittent catheter is in itself associated with a risk of developing UTIs 18, 19 by compromising the host defences in several ways. Catheterization obviates the protection from infections afforded by the length of urethra between the external and internal urethral openings as bacteria are deposited directly into the bladder. 20 A glycosaminoglycan layer coats the mucosal surface of the bladder in health, and a catheter traumatizes the bladder wall resulting in urothelial damage and compromise to this layer. 21 This increases the chances for bacterial penetration across the bladder wall. Mechanical cleansing of the LUT by natural voiding is yet another defence against infections that is compromised by an indwelling catheter. The biofilm that forms on the surface of the indwelling catheter creates an ideal environment for the growth of microorganisms and contributes to the emergence of resistance to host defences and antimicrobials. For this reason, intermittent catheterization is associated with a reduced risk of UTIs compared to an indwelling catheter. 18 Adopting a sterile technique (versus clean) further reduces the risk of UTI and/or bacteriuria compared with clean intermittent catheterization; however, this is usually not a feasible option in routine practice. 8
Management of UTIs in patients with MS
Asymptomatic bacteriuria
Treating asymptomatic bacteriuria is not associated with better outcomes and also results in resistant bacterial strains. 14 Therefore, asymptomatic bacteriuria in PwMS should not usually be treated. An exception may be in the setting of acute relapse where intravenous corticosteroid is considered. In this specific case, treatment may be contemplated if nitrites and leukocytes are present, to allow intravenous corticosteroid to be given 14, 22 (see section 'Suspected UTI in the patient with an MS relapse').
Symptomatic UTI
Antibiotic treatment is recommended for symptomatic UTIs (Figure 1 ). Empirical treatment is usually initiated with broad-spectrum antibiotics based on local susceptibility patterns or the patient's previous microbiology results, and the choice of antibiotics may need to be adjusted according to the results of urine culture (Figure 1 ). There is no consensus in the literature about the duration of treatment. By definition, UTIs occurring in PwMS are complicated, as they are associated with structural or functional abnormalities of the genitourinary tract in the presence of an underlying disease and therefore the risk of failing therapy is greater. 14 A 5-to 7-day course of antibiotic treatment is generally advised, which may be extended to 14 days according to the severity of infection. 8 The European Guidelines advise that symptomatic complicated UTI in the setting of an indwelling catheter should be treated with a narrowspectrum antibiotic whenever possible and modified based on culture and sensitivity results in order to prevent emergence of resistant bacterial strains. 14 
Suspected UTI in the patient with an MS relapse
In the case of suspected UTI in the context of a relapse, corticosteroid therapy need not be delayed and the initiation of antibiotic treatment is influenced by the results of urinalysis. Rakusa et al. 22 presented a urinalysis algorithm for UTI prior to initiation of corticosteroid therapy in PwMS who experienced relapse. In this study, the use of the urinalysis (positive if either leukocyte esterase or nitrites positive) had a specificity of 78% and a sensitivity of 75%. Negative predictive value of urinalysis was 96%. Neither the 3% of patients with false-negative urinalysis nor the 18% false-positive patients who were unnecessarily treated with antibiotics for 48 hours had any clinical adverse events. PwMS with systemic features of infection were excluded, for example, fever. Mahadeva et al. 23 reported a similar result in a large audit and also supported the initiation of corticosteroid treatment administered simultaneously with antibiotic treatment for the UTI, provided that the patient has no systemic symptoms of infection (e.g. fever, rigours and raised C-reactive protein).
However, diagnosing a relapse may sometimes be difficult in the presence of UTIs, especially in more disabled patients because UTIs may exacerbate MS-related LUT symptoms such as urinary urgency, frequency and incontinence. It is therefore important that all MS patients are questioned for the new onset or worsening of LUT and if confirmed, clinicians should have a high suspicion for UTI. 23 
Recurrent UTIs
Guidance for the management of recurrent UTIs is lacking. UTIs may exacerbate MS-related LUT symptoms such as urinary urgency, frequency and incontinence and infections may also predispose to complications of the upper urinary tract including stones, pyelonephritis and vesicoureteric reflux. 1 Management of LUT dysfunction. Based on a systematic review of existing literature up to 2014, the National Institute for Health Care and Excellence (NICE) guidelines state that PwMS and recurrent UTIs should be assessed by specialists for risk factors and offered appropriate treatment and guidance. 7 The occurrence of recurrent UTIs in PwMS may indicate suboptimal management of underlying LUT dysfunction, for example, high bladder pressure during storage and voiding and incomplete bladder emptying.
Different options are available to treat overactive bladder symptoms in MS patients, including oral antimuscarinic agents, tibial nerve stimulation, intradetrusor botulinum toxin A injections and sacral neuromodulation. 1, 17 Intradetrusor botulinum toxin A injections are highly effective for the management of detrusor overactivity in MS 24 and, in fact, treatment has been shown to reduce the incidence of symptomatic UTIs. The reasons for this are uncertain; however, the treatment is associated with an improvement in urodynamic parameters with an improved reservoir capacity at low pressure. 25 Ultrasonography of the bladder should be regularly performed to search for contributing factors, such as bladder stones. 1 The need for an indwelling catheter should be reviewed, 8 and, if required, the type of catheter used may be relevant as a hydrophilic catheter is associated with a lower rate of UTIs, at least in men. 26 Long-term indwelling urethral catheter should be avoided because of a higher risk of UTIs, urethral complications, bladder stones and cancer and rather the option of ISC or suprapubic catheter should be considered where possible. 14 Strategies to minimize infection should be rigorously followed including catheter insertion under antiseptic conditions, use of a closed catheter drainage systems with dependent drainage and regular changes of long-term catheters before likely blockage. 14 Patients with a large bladder capacity and low-pressure bladder may be managed using a flip-flow valve attached to the catheter after assessing suitability, thus avoiding the closed drainage bag. 7 From our experience, often these measures are insufficient to prevent UTIs and more specific preventative strategies may be required. However, these strategies remain largely unvalidated with a lack of high-grade recommendation in international guidelines.
Antibiotic prophylaxis. Continuous antibiotic prophylaxis for 6-12 months has been shown to be effective in reducing the rate of UTI during prophylaxis when compared to placebo in women without neurological disease. 27 However, their use in neurological patients with LUT dysfunction is uncertain. The use of oral antimicrobial prophylaxis for preventing UTIs in this group was not supported in a meta-analysis by Morton et al. 28 and is currently not recommended as a routine by NICE. 7 However, NICE guidelines recommend to consider antibiotic prophylaxis for patients who have a recent history of frequent or severe UTIs. 7 The concern about using antimicrobial prophylaxis is the emerging global problem of antimicrobial resistance as a twofold increase in resistant bacteria was reported with this approach. 28 The results of a recent observational prospective pilot study by Salomon et al. 29 however suggests that a weekly oral cyclic antibiotic (WOCA) regimen to prevent UTIs is both safe and efficacious in adult spinal cord-injured patients with LUT dysfunction performing ISC. The WOCA regimen consists of alternate administration of two antibiotics once a week over a period of at least 2 years. The antibiotics chosen were effective for preventing UTIs, with a dramatic reduction in the incidence of UTIs from 9.4 symptomatic infections per patient-year and 197 episodes of febrile UTI responsible requiring 45 hospitalizations before intervention to 1.8 symptomatic UTIs per patient-year, 19 episodes of febrile UTI and 7 hospitalizations afterwards. No severe adverse events and no new cases of colonization with multidrug resistant bacteria were reported. 29 This regimen requires to be studied in PwMS.
Cranberry. Few studies have evaluated cranberry in preventing UTIs in neurological patients. [30] [31] [32] A metaanalysis of randomized controlled trials including heterogeneous populations (patients with neurogenic bladder, elderly, pregnant women, women with recurrent UTIs and children) found that cranberry could reduce the number of UTIs by twofold 30 whereas a Cochrane review of 24 studies, with a total of 4473 subjects, revealed that cranberry products were of no benefit compared to placebo in most populations, 31 including spinal cord-injured patients (14.3%). These results are conflicting, but the studies did not focus specifically on the MS population. Only one study exclusively included PwMS in a multicentre, randomized, placebo-controlled, double-blind trial and could not demonstrate a reduction in UTI occurrence in 171 patients using cranberry extracts. 32 Therefore, the use of cranberry extracts for preventing UTIs is not supported by high-level evidence. D-Mannose. D-Mannose is a natural food supplement and is thought to work in a similar fashion to cranberry. Indeed, D-mannose binds to FimH at the tip of type 1 fimbria of enteric bacteria. 33 During bacterial colonization, FimH binds to carbohydrate-containing glycoprotein receptors on the epithelium of the urinary tract. 34 D-mannose shares similarity in structure to these urothelial glycoprotein receptors and therefore acts by competitively inhibiting bacterial adherence to carbohydrate-containing glycoprotein receptors on the epithelium of the urinary tract. 34 In a randomized controlled trial, 35 the daily intake of D-mannose powder 2 g for recurrent UTI prophylaxis in women without neurological disease was evaluated and a 45% relative risk reduction was reported, with results similar to the use of preventative nitrofurantoin. The use of D-Mannose in PwMS is currently being studied in an ongoing study (ClinicalTrials.gov NCT02490046).
Other approaches. A variety of approaches have been evaluated but without proven efficacy. Bladder irrigation and methenamine hippurate have been studied; however, there is insufficient evidence to support their use. 36, 37 The inoculation of apathogenic E. coli strains into the bladder has shown promise in initial randomized controlled studies; however, further studies are required before recommendations could be made. 38
Conclusion
UTIs are a major concern for PwMS and pose a challenge to the treating physician. Despite the significant impact that UTIs have, there is a dearth of studies around the diagnosis and management of UTIs in this group. This review provides an overview of the diagnosis, treatment and prevention of UTIs in PwMS. Known facts are the usefulness of urinalysis using to exclude a UTI and the non-treatment of asymptomatic UTIs except in the context of an acute MS relapse. Several options exist for the treatment of recurrent UTIs in MS; however, none has been validated. Further studies targeting this specific population suffering from UTIs are needed.
